Flu

Investigators found a significant association for febrile seizures, but not with epilepsy.

Issues around patient safety, proper administration, and monitoring need careful consideration from pharmacists and other health care providers for vaccination efforts.

The approval enables more convenient flu immunization options for patients.

Despite the new human case, which is not known to be related to animal exposure, the CDC emphasizes that risk to the general public remains low.

Lessons can be learned from Canadian models of influenza vaccine management, including proactive patient conversations and optimal workflows.

"Risk Less. Do More." plans to partner with national, state, and local organizations to provide resources to families and communities on how to protect themselves from RSV, influenza, and COVID-19.

Researchers assess the safety, tolerability, and immunogenicity of a single combination dose to evaluate its immunogenicity against SARS-CoV-2 and influenza.

RSV and influenza vaccines demonstrated hemagglutination inhibition titers that were noninferior to those with sequential administration.

Despite the century-long period of virus evolution, 6 of the 11 primates that received a cytomegalovirus-expressed flu vaccine survived the exposure to H5N1 flu.

Proper timing and vaccine selection are crucial for optimal immune responses.

With new guidance coming for the 2024-2025 season, pharmacists must stay up to date with current vaccine recommendations.

A strong recommendation from trusted health care professionals can make a difference.

Confusing product labeling and conflicting data can create challenges for patients.

Pharmacists have become the driving force behind immunizations in the US.

Many ways exist to best serve communities and the bottom line beyond vaccine ordering and increased staffing.

The 4-in-1 respiratory diagnostic test is either a single nasopharyngeal or anterior nasal swab that can confirm or rule out SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus with a single test.

Compared to other cases, the most recent patient reported more flu-like symptoms, including cough, congestion, watery eyes, and sore throat.

Although the CDC continues to emphasize that risk to humans is currently low, patients will have questions.

The FDA revisited the use of phenylephrine in OTC medications and called for more substantial evidence supporting its efficacy when taken orally.

Pharmacists' expertise is crucial in educating patients about regulatory changes, helping them navigate alternative formulations, and providing insights into evidence-based choices.

The SHARE model from the CDC involves personalizing recommendations for patients and their needs, addressing any concerns they may have, and explaining the risks of remaining unvaccinated.

The results found that the M2e nanoparticle injection could efficiently protect individuals from influenza A viruses.

Influenza, COVID-19, and respiratory syncytial virus will all peak in the coming months.

Fewer individuals have received the flu shot this season, compared to previous years.

Health policies to adapt to climate change must be altered to protect individuals with respiratory diseases in the warmer season.

Individuals that are younger in age, Black, have low levels of education, and low income were associated with a lower chance of getting the flu shot each year.

mRNA-1083 is an investigational combination vaccine designed to prevent influenza and COVID-19.

In a recent study, approximately 99% of children who received solid organ transplant and live vaccination against rubella had antibodies 1 to 3 months post-vaccination.

Engaging technicians in immunizations has been crucial to public health

mRNA-1083 (Moderna) was found comparable to the standard dose of Fluarix (GSK) in adults aged 50 to 64 years and Fluzone HD ( Sanofi) for influenza and Spikevax (Moderna) for COVID-19.